Bioequivalence Assessment Between Two Perampanel Oral Suspension Formulations

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
An open label, randomized, single-dose, two-sequences, two-periods, crossover study to assess the bioequivalence of perampanel in Lepsiramp 0.5mg/ml oral suspension (Test product) in comparison with Fycompa® 0.5mg/ml oral suspension (Reference product) in healthy subjects under fasting conditions.
Epistemonikos ID: 4b4648f8a6253a5c4ce564e1ae1427c27aa5c6e7
First added on: May 15, 2025